Ottobock invests in NeuroTech company ONWARD® Medical
more
Stories about Medizinische Behandlung
First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
morePress Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
moreSuccessful MDR Certification for AI Solution in Predicting Postoperative Complications – New Product Generation for Optimized Patient Safety
Berlin (ots) - x-cardiac, a leader in AI-based medical devices for the prediction of postoperative complications after cardiac surgery, is pleased to announce the successful MDR (Medical Device Regulation) certification of its new x-cardiac-platform. This certification introduces a completely new generation of ...
moreRHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
moreEpitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device
Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...
more
- 2
Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.
One documentmore - 2
Record financing rounds at the Munich biotech hub
One documentmore Bosch Healthcare Solutions GmbH
Near-patient PCR rapid test for whooping cough for Vivalytic by Bosch now available / World's first fully automated PCR test for detection of B. pertussis, B. parapertussis, B. holmesii
moreAcousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...
moreBosch Healthcare Solutions GmbH
PCR rapid test for 3 important gastroenteritis pathogens for Vivalytic by Bosch now available / World’s first fully automated PCR test for detection of C. difficile, norovirus, and rotavirus at the sampling point
morecanSERV to Accelerate Your Cancer Research - 2 Calls for Service Provision Open
2 Documentsmore
Press release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmorePress Release: Restless Legs Syndrome: Genetic Discoveries Advance Treatment and Risk Prediction
Researchers at Helmholtz Munich and the Technical University of Munich (TUM) together with international collaborators have conducted the largest genetic investigation of the restless legs syndrome to date. Their findings, ...
morePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmorecanSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore Bosch Healthcare Solutions GmbH
PCR rapid test for Candida auris for Vivalytic by Bosch now available / World’s first fully automated PCR test for detection of the multidrug-resistant fungus at the point of care
Waiblingen (ots) - - Vivalytic test detects Candida auris in under an hour at the point of care, making it the world’s first test suitable for screenings. - Candida auris infection rates are on the rise in Germany and can cause severe infections, for example of the bloodstream (sepsis). - Hospitals can use the new ...
more
Asthma in Children: Researchers Envision Novel Drug to Reduce the Risk of the Disease
Asthma in Children: Researchers Envision Novel Drug to Reduce the Risk of the Disease Scientists have reached a milestone in the research of childhood asthma. For the first time, they have clarified how a certain genetic defect in children initially leads to frequent infections and later to asthma. The study, published in the American Journal of Respiratory and ...
moreBosch Healthcare Solutions GmbH
Bosch and Randox: Strategic partnership brings highly multiplexing PCR to the point of care / BioMEMS technology enables fully automated, simultaneous testing for hundreds of genetic characteristics in just a few minutes
Waiblingen (ots) - - Bosch and Randox Laboratories Ltd. enter partnership for Vivalytic analysis platform to jointly invest around 150 million euros. - First test to feature novel BioMEMS technology will be a highly multiplexing sepsis IVD grade test. Bosch has agreed on a strategic partnership with Randox ...
moreDr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment
moreARTCLINE successfully completes capital increases of EUR 4.4 million
Rostock, Germany (ots) - Today ARTCLINE GmbH announced the successful completion of two further capital increases. In addition to the founders, in particular family offices from Germany participated in the first capital increase of EUR 0.8 million. In addition, a convertible loan from investors was transferred to equity, so that a second capital increase of EUR 3.6 ...
moreFennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with ...
more- 4
FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX
more
Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘
moreRising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Target
moreExtension of Wastewater Treatment Plant at Koehler Paper in Kehl
moreLeipzig Tourismus und Marketing GmbH
5Pioneering Heart Surgery and Medical Congresses in Leipzig
One documentmoreTherapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial
moreWhat Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications
more
Previous123456Next